AbbVie Reports Positive Phase 3 Results for Lutikizumab in Hidradenitis Suppurativa
AbbVie (ABBV) announced positive topline results from its Phase 3 INTREPID study evaluating lutikizumab for the treatment of adults with hidradenitis suppurativa. The trial successfully met its primary endpoint, demonstrating clinical efficacy at week 16. Data showed that 31.4% of patients treated with lutikizumab achieved a HiSCR75 response, compared to 23.4% in the control group. These results support the potential for lutikizumab to expand AbbVie's immunology portfolio and address unmet needs in inflammatory skin conditions.
Tickers: $ABBV
Topics: Drug efficacy Hidradenitis Suppurativa Phase 3 trial results